Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1519 Vaccine for Marburg Virus in Healthy Adults
NCT07919210Phase 1Not yet recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Marburg virus disease (MVD) (8 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions at 7 days, Number of Participants with Unsolicited Adverse Events at 28 days and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT07919210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919210.